• Mashup Score: 0

    Adolescents with moderate-to-severe atopic dermatitis (AD) saw major improvements after taking upadacitinib (Rinvoq) for 16 weeks, according to an analysis appearing recently in . The study combined data from three separate phase 3 studies, collectively taking place in more than 20 countries and comprising 552 adolescents (290 female; 262 male).

    Tweet Tweets with this article
    • What did the data indicate regarding #upadacitinib use in this adolescent population? #AtopicDermatitis #AADReadingRoom @AADskin #dermatology Read more: https://t.co/IuictqUOAP https://t.co/DWWAho7VZE

  • Mashup Score: 0

    Although major adverse cardiac events, malignancy and venous thromboembolism are more frequent in at-risk patients with rheumatoid arthritis, rates are similar between those receiving upadacitinib vs. adalimumab, according to data.

    Tweet Tweets with this article
    • Although major adverse ❤️cardiac events, malignancy and venous thromboembolism are more frequent in at-risk patients with rheumatoid #arthritis, rates are similar between those receiving #upadacitinib vs. #adalimumab https://t.co/9oy7YiZ7vH

  • Mashup Score: 0

    In a recent study published in RMD Open, the long-term safety profile of upadacitinib, a medication utilized in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD), was evaluated.

    Tweet Tweets with this article
    • In a recent study, the long-term safety profile of upadacitinib, a medication utilized in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and atopic dermatitis, was evaluated. https://t.co/OANkYuQPzE #dermtwitter #dermatology #upadacitinib